Testing
Falling triglycerides shift Lp(a) density in step with LDL, independent of apo(a) size, a study of 75 people (Arterioscler Thromb Vasc Biol 2001)
Original title: Changes in plasma triglyceride levels shift lipoprotein(a) density in parallel with that of LDL independently of apolipoprotein(a) size
This study examined whether metabolic events affecting LDL density also affect Lp(a) density, independent of apo(a) isoform size, in 75 subjects with Lp(a) protein levels of 7-50 mg/dL and a single apo(a) size isoform, using density gradient ultracentrifugation before and during triglyceride-lowering treatment. At baseline, Lp(a) peak density correlated strongly with LDL peak density (r=0.71, P<0.0001), and during treatment, changes in plasma triglycerides shifted Lp(a) peak density in parallel with LDL peak density, with an especially strong correlation (r=0.94, P<0.0001) in subjects with initial triglycerides around 300 mg/dL. In vitro, an apo(a) isoform with 14 kringle IV type 2 repeats incorporated similarly into LDL species across a density range of 1.035-1.057 g/mL. The findings show metabolically driven changes in Lp(a) density can occur independently of apo(a) size, a factor to consider when assessing Lp(a) cardiovascular pathogenicity in hypertriglyceridaemic patients.
Original abstract
Lipoprotein(a) [Lp(a)] represents a class of low density lipoprotein (LDL) particles that have as a protein moiety apolipoprotein B-100-linked covalently to a single molecule of apolipoprotein(a) [apo(a)], a specific multikringle protein of the plasminogen family. Lp(a) is polymorphic in density because of either the density heterogeneity of constitutive LDL, apo(a) size, or both. Authentic LDL also represents a set of heterogeneous particles whose density is affected by metabolic events. Whether in vivo these events may also affect Lp(a) density is not clearly established. To this effect, we studied 75 subjects with plasma Lp(a) protein levels between 7 and 50 mg/dL and containing a single apo(a) size isoform. We used density gradient ultracentrifugation to simultaneously monitor the changes in the peak density of LDL and Lp(a) at entry and during the course of treatments directed at reducing plasma triglyceride levels. In each case, we found that at entry, Lp(a) peak density was correlated with LDL peak density (r=0.71, P<0.0001) and that during treatment, changes in plasma triglycerides were associated with shifts of Lp(a) peak density that paralleled those of LDL peak density. A high correlation (r=0.94, P<0.0001) was particularly evident in subjects with initial plasma triglycerides in the 300-mg/dL range. In vitro assembly studies showed that an apo(a) isoform containing 14 kringle IV type 2 repeats, exhibited, on incubation with LDL, a comparable degree of incorporation into LDL species varying in density between 1.035 and 1.057 g/mL Taken together, our results indicate that metabolically dependent changes in the peak density of Lp(a) can occur independently of apo(a) size. These changes may have to be taken into account in assessing the cardiovascular pathogenicity of this lipoprotein particle in hypertriglyceridemic subjects.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.